| Literature DB >> 34900920 |
Hanadi Al Hamad1,2,3,4,5, Manal Mustafa Mohd Malkawi6, Jameela Ali A A Al Ajmi7, Mariam Nooh J H Al-Mutawa8, Sanjay Harish Doiphode9, Brijesh Sathian1.
Abstract
Introduction: The objective of this study is to investigate the COVID-19 outbreak and its successful containment in a long-term care facility, Qatar. Materials andEntities:
Keywords: COVID-19; Qatar; comorbidities; elderly; long term care; outbreak; prevention
Mesh:
Year: 2021 PMID: 34900920 PMCID: PMC8661591 DOI: 10.3389/fpubh.2021.779410
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1COVID-19 clinical profile of infected long-term care patients.
Figure 2Patient comorbidities.
Figure 3DM history and glucose profile of infected long-term care patients.
Socio-demographic and clinical profile.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Age (In years) | 47 | 40 | 109 | 84 | 101 | 76 | 77 |
| Gender | F | F | F | F | F | F | F |
| Comorbid conditions | Dyslipidemia, neurofibromatosis, seizure, poliomyelitis, kyphoscoliosis | Schizophrenia, type 2 DM, constipation | Dementia, CAD, seborrheic dermatitis scalp, contact dermatitis, stroke | Dementia, caecum cancer with metastasis, left occipital infarct. | COPD, CAD with 2 BMS to LAD, CKD, iron deficiency anemia, | HTN, asthma, DM, seizure, CKD, dementia, CAD, HFrEF (EF: 42%), CVA, intra cranial hemorrhage. | Type 2 DM, HTN, heart failure with EF 30%, bipolar disorder, Parkinson's, dementia, seizure, chronic bilateral diabetic feet, breast cancer (mastectomy), stroke |
|
| |||||||
| Total duration of symptoms prior to admission (days) | 0 (Inpatient) | 0 (Inpatient) | 0 (Inpatient) | 0 (Inpatient) | 0 (Inpatient) | 0 (Inpatient) | 0 (Inpatient) |
| Total duration of illness (days) | 21 | 20 (Reactive) | 33(Reactive) | 1 (Died) | 24 | 16 (Inconclusive) | 19 (Reactive) |
| Diagnosis | Body pain | Asymptomatic | Asymptomatic | Wheezing | Fever and shortness of breath | Low grade fever, Cough, vomiting | Asymptomatic |
| Symptoms | Body pain | Asymptomatic | Asymptomatic | Wheezing | Fever and shortness of breath | Low grade fever, Cough, vomiting | Asymptomatic |
| Temperature (degree Celsius) | 36.6 | 36.4 | 36.2 | 36.8 | 36.2 | 36.7 | 36.9 |
| Blood pressure (mmHg) | 108/68 | 106/68 | 105/60 | 122/76 | 110/72 | 114/54 | 132/77 |
| Respiratory rate (breaths per minute) | 19 | 18 | 18 | 19 | 18 | 18 | 19 |
| Heart rate (Beat per minute) | 78 | 91 | 78 | ||||
| Chest Xray | Ground-glass appearance of the lungs | Ground-glass appearance of the lungs, diffuse interstitial pattern versus pulmonary fibrosis. | Increased density of interlobular septa and peri-broncho vascular space in relation to linear interstitial pattern | Slight increase in the bilateral mid and lower zones peripheral alveolar airspace opacities with more atelectatic bands | Lung reticulation and interstitial markings | ||
| Chest CT | Pulmonary infiltration/ | ||||||
NA, data Not Available.
Laboratory Investigations.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| White blood cells count (x103/μl) | 4-10 | 2.3 | 2.75 | 3.37 | 6.8 | 8.2 | 5.1 | |
| Hemoglobin (gm/dl) | 13–17 | 13.2 | 11.9 | 9.1 | 9.6 | 12.3 | 13.8 | |
| Platelet count (x103/μl) | 150–400 | 175 | 152 | 153 | 387 | 160 | ||
| Absolute neutrophil count (x103/μl) | 2–7 | 37.7 | 44.7 | 63.7 | 54.5 | 73.6 | 68.1 | |
| Lymphocyte Count (x103/μl) | 1–3 | 45.6 | 38.1 | 21.9 | 33.7 | 13.5 | 16.8 | |
| Urea (mmol/L) | 3–9 | 2.7 | 6.7 | NA | 14 | 8.3 | 2.9 | |
| Creatinine (μmol/L) | 63.6–110.5 | 43 | 85 | NA | 150 | 85 | 50 | |
| Sodium | NA | 134 | 144 | NA | 139 | 129 | 3.9 | |
| Potassium | 3.9 | 4.4 | 4.9 | 5.4 | 91 | |||
| Total bilirubin | <2 | <3 | 4 | 6 | 3 | |||
| Albumin | 32 | 38.5 | 27 | 32 | 30 | |||
| ALT (U/L) | 0–55 | 24 | 15 | 6 | 12 | 12 | ||
| AST (U/L) | 5–34 | 39 | 25 | 20 | 18 | NA | ||
| CK | NA | NA | 26 | 697 | NA | NA | ||
| C-reactive protein (mg/l) | 0–5 | 32.1 | 5 | 40 | 8.2 | 4.1 | ||
| Influenza A | NA | Negative | NA | NA | NA | NA | NA | |
| Influenza B | NA | Negative | ||||||
| Mechanical ventilation | No | No | No | No | No | No | No | No |
NA, data Not Available.
Treatment and outcome.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Azithromycin 500 mg daily | No | No | No | No | 7 days | No | No |
| Hydroxychloroquine 400 mg | 1 day | 2 days | 7 days | No | 7 days | 4 days | 6 days |
| Antivirals | No | No | No | No | No | No | No |
|
| |||||||
| ICU admission | No | No | No | No | No | No | No |
| Invasive, non-invasive ventilation or supplemental oxygen | No | No | No | No | No | No | No |
| Duration of symptoms in total (days) | 21 | 20 (reactive) | 33 (reactive) | 1 (died) | 24 | 16 (inconclusive) | 19 (reactive) |
Records of seven COVID-19 positive patients and three patient attendees.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | 07-June-2020 | + | 27.23 | Symptomatic with body malaise and pain. |
| 2 | 08-June-2020 | + | 19.71 | Asymptomatic |
| 3 | 08-June-2020 | + | 20.44 | |
| 4 | 08-June-2020 | + | 14.9 | |
| 5 | 08-June-2020 | + | 24.75 | |
| 6 | 12-June-2020 | + | 21.96 | Symptomatic after shifting to Unit G1. |
| 7 | 12-June-2020 | + | 20.52 | |
| Records of three COVID-19 positive patient attendees | ||||
| 1 | 08-June-2020 | + | 18.55 | - |
| 2 | 08-June-2020 | + | 18.51 | - |
| 3 | 15-June-2020 | + | 18.35 | - |
Positive staff with CT values.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| STAFF 1 | 17.4 | 29.8 | 31.6 | |||||
| STAFF 2 | 18.1 | 29.8 | NEGATIVE | |||||
| STAFF 3 | 20.2 | 24.5 | 27.4 | |||||
| STAFF 4 | 26.1 | 23.7 | 32.1 | |||||
| STAFF 5 | 25.4 | 28.6 | 36 | |||||
| STAFF 6 | 27.3 | 23.8 | 31 | |||||
| STAFF 7 | 34.6 | 23.7 | 30.4 | |||||
| STAFF 8 | 26.3 | 16.8 | 18.7 | |||||
| STAFF 9 | 19.1 | 18.5 | 22.3 | |||||
| STAFF 10 | 27.1 | 16.3 | 17.7 | |||||
| STAFF 11 | 38.1 | 18.8 | 20.7 | |||||
| STAFF 12 | ||||||||
| STAFF 13 | NEGATIVE | NEGATIVE | NEGATIVE | 19.1 | ||||